BioTrinity 2010: UK Company Showcase - Biotech and MedTech
The BioTrinity 2010 Company Showcase is a unique opportunity to take in 36 corporate/investor presentations from the best companies from the UK's most successful bioclusters and partner with them. This year we will again feature a mostly hand-selected line-up of the Most Promising Companies over April 13-14th 2010. Day one will feature drug discovery and development as well as platform technologies, and Day Two will feature medtech as well as platform companies. Do contact us soon if you wish to be considered for one of the few remaining presenting slots, since over 80% are already allocated and a number of companies are being considered for what remains. We are also delighted to have accepted our first presentation from the MassBio cluster in Boston, US.
|
|
Tuesday, 13th April 2010 |
|
12.00 |
Day 1 - BioTrinity 2010 Company Showcase (sponsored by Shire): From Concept to Patient - Biotechnology |
 |
12.00 Shire - David Colpman, Shire Pharmaceuticals- Introducing the Company Showcase |
 |
12.10 BioVex - Colin Love, SVP |
 |
12.20 Chroma Therapeutics - Ian Nicholson, CEO |
12.30 - 13.30 |
Lunch and Exhibition Viewing |
 |
13.30 Summit plc - Steven Lee, CEO |
 |
13.40 Saturn Biosciences - Nigel Courtenay-Luck, Co-Founder & CSO |
 |
13.50 Synairgen Research - Philip Monk, Chief Scientific Officer |
 |
14.00 Syntaxin - Melanie Lee, CEO |
 |
14.10 Aquapharm Biodiscovery - Andrew Mearns Spragg, CEO |
 |
14.20 Hypha Discovery - Liam Evans, CEO |
 |
14.30 Karus Therapeutics - Simon Kerry, CEO |
 |
14.40 CellCentric - David Knowles, CSO |
15.00 - 15.30 |
|
 |
14.50 Pro-Cure Therapeutics - Michael J. Mclean, CEO |
|
15.30 Ixo Limited - Douglas Thomson, CEO |
 |
15.40 Technomark Life Sciences - Allen Hakimi, MD |
 |
15.50 BigDNA - John March, CEO |
|
16.00 Isogenica - Ambili Nair, Business Development |
 |
16.10 Physiomics - Dr Christophe Chassangnole, COO |
 |
16.20 Cyprotex - Dr Anthony D Baxter, CEO |
 |
16.30 Oxford Nanopore - Jim McDonald, Finance Director |
 |
16.40 London Genetics - Dominique Kleyn, CEO |
 |
16.50 Inhibox - Paul Davie, CCO |
17.00 - 18.00 |
Networking Reception Sponsored by Shire Pharmaceuticals in the Exhibition Hall |
19.30 - 22.30 |
Reception and Gala Dinner in the Hennessy Suite, Hampshire Stand |
|
Wednesday, 14th April 2010 |
|
13.30 |
Day 2 - BioTrinity 2010 Company Showcase: From Concept to Patient - MedTech
|
 |
13:30 Glide Pharma -Simon Jones, CFO |
 |
13:40 G-Nostics - Mark Tucker, CEO |
 |
13:50 RepRegen - Ian Brown, CEO |
 |
14:00 Oxford Contrast Molecular Diagnostics - Richard Jones, CEO |
 |
14:10 Vivacta - Neil Butler, CEO |
 |
14:20 Organox - Les Russell, CEO |
 |
14:30 OrthOx - Nick Skaer, CEO |
 |
14:40 Oxford Immunotec -Peter Wrighton-Smith, CEO |
 |
14:50 Glysure -Chris Jones, CEO |
15.00 - 15.30 |
Refreshments and Networking |
15.30 |
Day 2 - BioTrinity 2010 Company Showcase: From Concept to Patient - Biotech continued...
|
 |
15:30 Domainex - Eddy Littler, CEO |
 |
15:40 Advanced Proteome Therapeutics Inc.(MA, USA) - Alexander Krantz, CEO/President |
 |
15:50 Polytherics - Sally Waterman, COO |
 |
16:00 Lipoxen - Scott Maguire, CEO |
 |
16:10 Pharmidex - Gary Manchee, Global Head of Business Development |
 |
16:20 Immune Targeting Systems - Carlton Brown, CEO |
16.30 |
Conference Close Drinks |
Overview of the company showcase
The majority of companies were hand-selected on the basis of their fundraising or revenue streams, USP, deal-making, innovation, and IP. The focus is on drug discovery and development, diagnostics and medical technology. The format of the presentations is an 8 minut presentation, including Q&A. Click on each speaker name to read biographies - further speaker biographies will be added as we receive them.
Selection Process
The vast majority of companies listed above are hand-picked by our team, although a small number of slots are reserved for applicants. Please contact our CEO Jon Rees on +44 (0)1865 594642 to discuss and apply for a speaking slot or make an Online Application. An informed decision will be made based upon information supplied by companies, business intelligence, potentially with reference to the expert knowledge of members of the OBN Advisory Board and our extended BioTrinity Advisory Board. As with other delegates, speakers from selected companies must complete a paid registration to be admitted and benefit from partnering at BioTrinity 2010.
Companies who are not selected to present are encouraged to participate in the one-to-one partnering elements of the meeting for the purposes of business development.
Criteria for Selection
- Consideration will be given to company's USP, or the USP of their leading product, the route-to-market, exit route and milestones.
- Consideration is given to revenue streams or demonstrated fund-raising ability, and proximity to market
- Efficient use of funding
- Recent deal-making success
- Innovation in product or business strategy
- Preference is given to companies based in the South-East UK
- Preference is given to companies which have been trading for less than 7 years
- Intellectual property to meet business strategy
